Clinical evaluation of dried blood spots for the determination of tamoxifen and endoxifen levels

• Conditions: 10006291; breast cancer; mamma carcinoma

• Registration Number: NL-OMON40928
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

- Treated with tamoxifen
- Age 18 years or older
- Able and willing to give informed consent
- Able and willing to undergo a fingerprick for dried blood spot sampling

Exclusion Criteria

none

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Ratio of the DBS and serum concentrations of tamoxifen and endoxifen</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Percentage of patients that obtains a DBS by self-sampling at home<br /><br>- Percentage of patients that provides DBS samples useful for analysis </p><br>